Syndax Pharmaceuticals SNDX Business Segments — Stock Based Compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:StockBasedCompensation.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's business segments — stock based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's business segments — stock based compensation?
- Syndax Pharmaceuticals (SNDX) reported business segments — stock based compensation of $12.05M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — stock based compensation changed year-over-year?
- Syndax Pharmaceuticals's business segments — stock based compensation increased by 16.1% year-over-year, from $10.38M to $12.05M.
- What does business segments — stock based compensation mean?
- This metric reflects the non-cash expense recognized for equity-based awards granted to employees and executives within the cancer therapeutics segment. It is a key component of total compensation strategy used to attract and retain talent in the competitive biopharmaceutical industry. Investors analyze this to understand the impact of dilution and non-cash charges on overall profitability.